|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/10/21 Omega Healthcare Investors Inc. 8-K:1,2,9 3/10/21 14:1M Toppan Merrill/FA |
Document/Exhibit Description Pages Size 1: 8-K Current Report HTML 37K 2: EX-4.1 Instrument Defining the Rights of Security Holders HTML 299K 3: EX-5.1 Opinion of Counsel re: Legality HTML 19K 4: EX-5.2 Opinion of Counsel re: Legality HTML 26K 5: EX-8.1 Opinion of Counsel re: Tax Matters HTML 24K 10: R1 Cover HTML 48K 12: XML IDEA XML File -- Filing Summary XML 13K 9: XML XBRL Instance -- tm218752d1_8k_htm XML 15K 11: EXCEL IDEA Workbook of Financial Reports XLSX 6K 7: EX-101.LAB XBRL Labels -- ohi-20210310_lab XML 97K 8: EX-101.PRE XBRL Presentations -- ohi-20210310_pre XML 65K 6: EX-101.SCH XBRL Schema -- ohi-20210310 XSD 13K 13: JSON XBRL Instance as JSON Data -- MetaLinks 25± 34K 14: ZIP XBRL Zipped Folder -- 0001104659-21-034486-xbrl Zip 91K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): i March 10, 2021
i OMEGA HEALTHCARE INVESTORS, INC.
(Exact name of registrant as specified in its charter)
| i Maryland | i 1-11316 | i 38-3041398 |
| (State or other jurisdiction
of incorporation) |
(Commission File Number) | (IRS Employer Identification No.) |
i Hunt Valley, i Maryland i 21030
(Address of principal executive offices / Zip Code)
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| i ¨ | Written communications pursuant to Rule 425 under the Securities Act. |
| i ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act. |
| i ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act. |
| i ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act. |
Securities registered pursuant to Section 12(b) of the Securities Exchange Act of 1934:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| i Common Stock, $.10 par value | i OHI | i New York Stock Exchange |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
C:
Item 1.01. Entry into a Material Definitive Agreement.
On March 10, 2021, Omega Healthcare Investors, Inc. (“Omega”) completed an underwritten public offering of $700 million aggregate principal amount of its 3.250% Senior Notes due 2033 (the “Notes”). The Notes are governed by the terms of the Indenture, dated as of March 10, 2021, among Omega, as issuer, the subsidiary guarantor identified below, and U.S. Bank National Association, as trustee (the “Trustee”).
The Notes are guaranteed by Omega’s subsidiary, OHI Healthcare Properties Limited Partnership, and will be guaranteed by Omega’s existing and future subsidiaries that guarantee unsecured indebtedness for money borrowed of Omega in a principal amount at least equal to $50 million. The public offering price of the Notes was 99.304% of the principal amount.
Omega expects to use the net proceeds from the Notes offering (i) to repay its British Pounds Sterling denominated borrowings under its credit facilities and (ii) to fund the purchase price for its previously announced tender offer to purchase for cash a portion of its 4.375% Senior Notes due 2023 and the payment of accrued interest and related fees, premiums and expenses in connection therewith. Omega intends to use any remaining net proceeds, including in the event that it does not achieve full participation in the tender offer, to repay a portion of outstanding borrowings under its credit facilities and for general corporate purposes, which may include future acquisition or investment opportunities.
The Notes mature on April 15, 2033, and bear interest at a rate of 3.250% per annum, payable semi-annually in cash, in arrears, on April 15 and October 15 of each year, commencing on October 15, 2021.
The Notes are Omega’s unsecured senior obligations and rank equally in right of payment with all of Omega’s existing and future senior debt and senior in right of payment to all of Omega’s existing and future subordinated debt. The Notes are effectively subordinated in right of payment to any of Omega’s existing and future secured indebtedness to the extent of the value of the assets securing such indebtedness. The Notes are structurally subordinated to all existing and future liabilities (including indebtedness, trade payable and lease obligations) of each of Omega’s non-guarantor subsidiaries.
Omega may redeem some or all of the Notes prior to January 15, 2033 (the “Par Call Date”) at a price equal to 100% of the principal amount of Notes to be redeemed, plus a “make-whole” premium calculated by reference to U.S. Treasuries with a maturity comparable to the Par Call Date (and assuming that such Notes matured, and that interest on such Notes was payable, on the Par Call Date), plus accrued and unpaid interest, if any, to, but not including, the applicable redemption date. The Notes will be redeemable at any time on or after the Par Call Date at a redemption price equal to 100% of the principal amount thereof plus accrued and unpaid interest, if any, to, but not including, the applicable redemption date.
The Indenture contains certain covenants that limit the ability of Omega and certain of its subsidiaries to, among other things, incur additional indebtedness and merge, consolidate or sell all or substantially all of the assets of Omega or its subsidiary guarantors’ assets. The Indenture also contains a covenant requiring Omega and its subsidiaries to maintain a certain amount of unencumbered assets.
C:
C: 2
The Indenture contains customary events of default including, without limitation, failure to make required payments, failure to comply with certain agreements or covenants, cross-acceleration to certain other indebtedness in excess of specified amounts and certain events of bankruptcy and insolvency. An event of default under the Indenture will allow either the Trustee or the holders of at least 25% in aggregate principal amount of the then outstanding Notes to accelerate, or in certain cases, will automatically cause the acceleration of, the amounts due under the Notes.
The offering was made pursuant to Omega’s automatic shelf registration statement on Form S-3 (Registration No. 333-228321) and a related prospectus supplement filed with the Securities and Exchange Commission.
The foregoing description of the Notes and Indenture is qualified in its entirety by reference to the actual text of the Indenture (including the forms of Notes included therein), which is filed herewith as Exhibit 4.1 and is incorporated herein by reference.
Item 2.03. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.
The disclosure contained in “Item 1.01. Entry into a Material Definitive Agreement” is incorporated in this Item 2.03 by reference.
Item 9.01 Financial Statements and Exhibits.
| (d) | Exhibits. |
| Exhibit Number | Description | |
| 4.1 | Indenture dated as of March 10, 2021, among Omega Healthcare Investors, Inc., OHI Healthcare Properties Limited Partnership, as Subsidiary Guarantor, and U.S. Bank National Association, as Trustee | |
| 5.1 | Opinion of Shapiro Sher Guinot & Sandler, P.A. | |
| 5.2 | Opinion of Bryan Cave Leighton Paisner LLP | |
| 8.1 | Tax Opinion of Bryan Cave Leighton Paisner LLP | |
| 23.1 | Consent of Shapiro Sher Guinot & Sandler, P.A. (Included in Exhibit 5.1) | |
| 23.2 | Consent of Bryan Cave Leighton Paisner LLP (Included in Exhibit 5.2 and 8.1) | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
C:
3
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the co-registrants have duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| OMEGA HEALTHCARE INVESTORS, INC. | ||
| Dated: March 10, 2021 | By: | /s/ Robert O. Stephenson |
| Robert O. Stephenson | ||
| Chief Financial Officer, Treasurer and Assistant Secretary | ||
C:
C:
| This ‘8-K’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| 4/15/33 | None on these Dates | |||
| 1/15/33 | ||||
| 10/15/21 | ||||
| Filed on / For Period end: | 3/10/21 | |||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 2/12/24 Omega Healthcare Investors Inc. 10-K 12/31/23 156:32M 2/14/23 Omega Healthcare Investors Inc. 10-K 12/31/22 150:30M 2/17/22 Omega Healthcare Investors Inc. 10-K 12/31/21 155:28M 12/07/21 Omega Healthcare Investors Inc. S-3ASR 12/07/21 7:2M Toppan Merrill/FA 8/05/21 Omega Healthcare Investors Inc. 424B5 1:688K Toppan Merrill/FA 5/20/21 Omega Healthcare Investors Inc. 424B2 1:437K Toppan Merrill/FA 5/13/21 Omega Healthcare Investors Inc. S-3ASR 5/13/21 4:364K Toppan Merrill/FA 5/04/21 Omega Healthcare Investors Inc. 10-Q 3/31/21 96:12M |